Second-generation iminoxylitol-based pharmacological chaperones for the treatment of Gaucher disease (Q83317136)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

Second-generation iminoxylitol-based pharmacological chaperones for the treatment of Gaucher disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Farah Oulaïdi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Sophie Front-Deschamps

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Estelle Gallienne

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Kyoko Ikeda

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Naoki Asano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Philippe Compain

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Olivier R Martin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

4 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

353-361

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

The molecular basis of lysosomal storage diseases and their treatment

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Protein misfolding disorders: pathogenesis and intervention

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Sphingolipids—Their Metabolic Pathways and the Pathobiochemistry of Neurodegenerative Diseases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Lysosomal storage diseases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Sphingolipid metabolism diseases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Glycosphingolipidoses: beyond the enzymatic defect

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Glycosphingolipids--nature, function, and pharmacological modulation.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.201000469

1 reference

7 January 2021

Mutations causing Gaucher disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

New directions in the treatment of Gaucher disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Gaucher disease: unmet treatment needs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Limitations of enzyme replacement therapy: current and future

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Lysosomal storage diseases: natural history and ethical and economic aspects

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Inhibition of Glycosphingolipid Biosynthesis: Application to Lysosomal Storage Disorders

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Therapeutic applications of imino sugars in lysosomal storage disorders

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Substrate reduction therapy for glycosphingolipid storage disorders

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Substrate reduction therapy in mouse models of the glycosphingolipidoses

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Substrate reduction therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Pharmacologic chaperoning as a strategy to treat Gaucher disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Isofagomine induced stabilization of glucocerebrosidase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Total asymmetric synthesis of (-)-conduramine B-1 and of its enantiomer. N-Benzyl derivatives of conduramine B-1 are beta-glucosidase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Rational design and synthesis of highly potent beta-glucocerebrosidase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Aminocyclitols as pharmacological chaperones for glucocerebrosidase, a defective enzyme in Gaucher disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Synthesis of 4-O-glycosylated 1-deoxynojirimycin derivatives as disaccharide mimics-based inhibitors of human beta-glucocerebrosidase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Synthesis of new beta-1-C-alkylated imino-L-iditols: A comparative study of their activity as beta-glucocerebrosidase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

A general synthesis of iminosugars

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

General access to iminosugar C-glycoside building blocks by means of cross-metathesis: a gateway to glycoconjugate mimetics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Alpha-1-C-alkyl-1-deoxynojirimycin derivatives as potent and selective inhibitors of intestinal isomaltase: remarkable effect of the alkyl chain length on glycosidase inhibitory profile

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Synthesis of polyhydroxylated piperidines and evaluation as glycosidase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Studies on synthesis of 3-O-alkyl-D-glucose and 3-O-alkyl-D-allose derivatives and their biological activities.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Solution-phase library synthesis of furanoses

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Enantiospecific synthesis of the phospholipase A2 inhibitor (-)-cinatrin B

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000469

7 January 2021

Identifiers

DOI

10.1002/CMDC.201000469

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21275057%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference